Rodríguez-Alcalde Daniel, Castillo-López Guillermo, López-Vicente Jorge, Hernández Luis, Lumbreras-Cabrera Mercedes, Moreno-Sánchez Diego
Digestive Disease Section, Hospital Universitario de Móstoles, 28935 Móstoles, Spain.
Digestive Disease Section, Hospital Santos Reyes, 09400 Aranda de Duero, Spain.
Cancers (Basel). 2021 Mar 3;13(5):1066. doi: 10.3390/cancers13051066.
Serrated polyposis syndrome (SPS) implies a slightly elevated risk of colorectal cancer (CRC) during endoscopic follow-up, but its natural course is still not well known. The main objective of this study was to describe the long-term risk of developing advanced neoplasia (AN) in these patients. Until October 2020, individuals who fulfilled 2010 WHO criteria I and/or III for SPS were retrospectively recruited. We selected those under endoscopic surveillance after resection of all lesions >3 mm in a high-quality colonoscopy. We excluded patients with total colectomy at diagnosis and those with any interval between colonoscopies >3.5 years. We defined AN as advanced serrated polyp (≥10 mm and/or with dysplasia), advanced adenoma, or CRC. In 109 patients, 342 colonoscopies were performed (median = 3, median interval = 1.8 years) during a median follow-up after colonic clearance of 5.0 years. Five-year cumulative incidences of AN were 21.6% globally, and 5.6%, 10.8%, and 50.8% in patients who fulfilled criterion I, III, and both, respectively ( < 0.001). No CRC was diagnosed and only 1 (0.9%) patient underwent surgery. In conclusion, cumulative incidences of AN could be lower than previously described, at least in patients who fulfil the 2010 WHO criterion III alone. Therefore, low-risk individuals might benefit from less stringent surveillance.
锯齿状息肉病综合征(SPS)在内镜随访期间意味着患结直肠癌(CRC)的风险略有升高,但其自然病程仍不清楚。本研究的主要目的是描述这些患者发生高级别瘤变(AN)的长期风险。截至2020年10月,对符合2010年世界卫生组织SPS标准I和/或III的个体进行了回顾性招募。我们选择了在高质量结肠镜检查中切除所有直径>3 mm病变后接受内镜监测的患者。我们排除了诊断时行全结肠切除术的患者以及结肠镜检查间隔时间>3.5年的患者。我们将AN定义为高级别锯齿状息肉(≥10 mm和/或伴有发育异常)、高级别腺瘤或CRC。109例患者在结肠清除术后的中位随访期为5.0年期间共进行了342次结肠镜检查(中位数 = 3,中位间隔时间 = 1.8年)。AN的5年累积发病率全球为21.6%,符合标准I、III以及两者均符合的患者分别为5.6%、10.8%和50.8%(<0.001)。未诊断出CRC,仅1例(0.9%)患者接受了手术。总之,AN的累积发病率可能低于先前描述的,至少在仅符合2010年世界卫生组织标准III的患者中如此。因此,低风险个体可能受益于不太严格的监测。